Definitely stock price can be affected by media hype, buying the...

Definitely stock price can be affected by media hype, buying the story, etc. And certainly the first clinical trials were a stuff up. The people running it mustn't have been properly educated based on study protocol, quiet background noise, etc. And definitely that sort of issue is something users may encounter. The system needs to be robust enough to inform people when the background environment is too noisy.

But this is in the past. Clinical trials are expensive and take a lot of time. Regulatory approvals are expensive and take a lot of time. ResApp has overcome these major hurdles, and I maintain that even without revenue, the data and achievements so far represent huge intrinsic value.

Commercialisation is the next hurdle - congratulations on keeping your nerves through the dips and hopefully you see some return on investment, I think this will be the year!

(Edit) I know it was just an example you gave, but changing address isn't as simple as it seems. Regulatory bodies are slow and pedantic. And if an updated certificate from the notified body in Europe is required, it's almost totally out of ResApps hands. Things are crazy over there. Trust me.